What is the 13F Pro Quality Score for PDEX?

13F Pro ranks PRO DEX INC (PDEX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PDEX's current score at https://13fpro.ai/company/PDEX (free sign-up required for the full ranking).

Where does 13F Pro source PDEX data?

All PRO DEX INC fundamentals and ownership data come directly from SEC EDGAR. PRO DEX INC files with the SEC under CIK 788920. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PDEX in?

PRO DEX INC (PDEX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives PDEX's revenue?

Per PRO DEX INC's latest 10-Q filed with the SEC on 2026-04-30, the biggest revenue drivers are: Medical device products ($16.2M, +36% YoY); Repairs ($2.7M, -48% YoY); NRE & Prototype ($531K, +186% YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/PDEX.

What are PDEX's largest expenses?

PRO DEX INC's latest 10-Q reports these as the largest expense items: Cost of sales ($13.8M, +19% YoY); General and administrative expenses ($2.2M, +98% YoY); Research and development costs ($827K, -13% YoY). Sourced directly from SEC EDGAR filing text for Q3 FY2026 (quarter ended March 31, 2026).

How often is PDEX research updated on 13F Pro?

PDEX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

PRO DEX INC(PDEX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaqsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 788920 PDEX stock profile & AI dashboard →

13F Pro Quality Score

62.2/100

Rank #728 of 2,961 stocksTOP 25%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

79.9/100

Profitability

81.1/100

Balance Sheet

95.8/100

Earnings Quality

56.0/100

Free Cash Flow

52.8/100

Institutional Flow

21.9/100

Revenue Scale

12.6/100

Dilution Risk

60.6/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why PDEX Scores 62/100

exact factor attribution · 2026-09-11

PDEX's composite is driven by revenue growth and profitability, held back by scale and institutional flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Revenue growth

+6.0 pts

80th pct

Profitability

+4.7 pts

81th pct

Capital efficiency

+4.6 pts

96th pct

Earnings growth

+2.4 pts

98th pct

Earnings quality

+0.6 pts

56th pct

Shareholder dilution

+0.5 pts

61th pct

Free cash flow

+0.4 pts

53th pct

Institutional flow

-1.4 pts

22th pct

Scale

-5.6 pts

13th pct

Latest change (2026-09-03): 61 → 63 · ↑ Dilution 62→74

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

PDEX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for PRO DEX INC (PDEX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PDEX at 62.2/100 on a 32-signal composite quality model, placing it at rank #728 of 2,961 stocks — the top 25% of the AI-ranked universe. PDEX scores in the top quartile across balance sheet strength (95.8), profitability (81.1), revenue growth (79.9). Areas of concern include revenue scale (12.6) and institutional flow (21.9), which score below median versus the broader universe. Based on the latest XBRL financial filings (Q2 2026), PRO DEX INC reports quarterly revenue of $20.4M, net income of $2.9M, an operating margin of 17.3%. Top institutional holders of PDEX by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, DIMENSIONAL FUND ADVISORS, based on the most recent SEC filings. PDEX trades on the Nasdaq exchange and files with the SEC under CIK 788920. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PDEX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for PRO DEX INC directly from SEC EDGAR. PRO DEX INC's 13F Pro composite quality score has ranged between 45 and 63 since 2024, currently 62.2 — an improving long-term trajectory across 55 quarterly and live scoring snapshots.

What's Driving PDEX's Business? Latest 10-Q Breakdown

✓ 33/33 datapoints verified

AI-extracted from PRO DEX INC's 10-Q filed 2026-04-30 — Q3 FY2026 (quarter ended March 31, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Net sales rose 15% YoY to $19.9M on a 36% jump in medical device sales tied to the largest customer's contract extension, while repair revenue fell 48% as that customer shifts to next-gen handpieces.

Biggest Revenue Drivers

Medical device products$16.2M+36% YoY

Increase driven by higher orthopedic sales to largest customer following contract extension through 2028

Repairs$2.7M-48% YoY

Fewer repairs of the legacy orthopedic handpiece sold to largest customer

Biggest Revenue Drivers

Total revenue: $19.9M+15% YoY

Medical device products$16.2M+36% YoY

Increase driven by higher orthopedic sales to largest customer following contract extension through 2028

Within Medical device products

Orthopedic$13.1M+$4.5M YoY

Largest customer's medical device revenue increased on contract amendment extending supply through 2028

Repairs$2.7M-48% YoY

Fewer repairs of the legacy orthopedic handpiece sold to largest customer

NRE & Prototype$531K+186% YoY

Increase in billable contracts for various NRE projects undertaken for customers

Industrial and scientific$472K+78% YoY

Primarily due to inclusion of newly acquired APM sales since the February 9, 2026 acquisition date

Largest Expense Items

Cost of sales$13.8M+19% YoY

Consistent with 15% revenue increase; under-absorption of manufacturing costs rose $398K

General and administrative expenses$2.2M+98% YoY

Higher personnel costs, $233K of APM G&A, $250K consulting fees to APM's seller, and a $225K CEO bonus accrual

Research and development costs$827K-13% YoY

More project costs reclassified to cost of sales and reduced intellectual property legal costs

Margins: Gross margin fell 2 points YoY to 31% due to unfavorable product mix and higher manufacturing cost under-absorption, even though gross profit grew 6% on higher medical device revenue.

Watch Items from the Filing

Customer 1 represented 79% of net sales ($15.65M) and 75% of gross accounts receivable in the quarter, up from 77% a year ago.
Backlog stood at approximately $39.0M, with $15.6M scheduled for delivery in Q4 FY2026, supported by the customer contract extension through 2028.
Company took on new debt to fund the $8.65M APM acquisition: a $6.65M UMB Term Loan D plus a $2.0M subordinated note at 8% interest.
Quarter's income included a non-operating $2.3M gain from a Monogram/Zimmer Biomet contingent value right milestone, not from core operations.
Three suppliers accounted for 38% of inventory purchases in the quarter, with Supplier 1 alone at 21%.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$20.4M

Net Income

Q2 2026

$2.9M

Free Cash Flow

Q2 2026

$-476.0K

Operating Margin

Q2 2026

17.3%

ROIC

Q2 2026

21.7%

D/E Ratio

Q2 2026

0.37

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

+16.5% YoY

$77.5MFY 2026

FY23 $46.1MFY24 $53.8MFY25 $66.6MFY26 $77.5M

Net Income

+52.2% YoY

$13.7MFY 2026

FY23 $7.1MFY24 $2.1MFY25 $9.0MFY26 $13.7M

Operating Income

+21.5% YoY

$13.0MFY 2026

FY23 $5.8MFY24 $7.2MFY25 $10.7MFY26 $13.0M

EPS (Diluted)

+54.3% YoY

$4.12FY 2026

FY23 $1.95FY24 $0.60FY25 $2.67FY26 $4.12

Total Assets

+21.8% YoY

$74.5MFY 2026

FY23 $51.8MFY24 $52.5MFY25 $61.2MFY26 $74.5M

Total Debt

+13.5% YoY

$17.5MFY 2026

FY23 $12.8MFY24 $12.0MFY25 $15.4MFY26 $17.5M

Op. Cash Flow

+530.6% YoY

$7.2MFY 2026

FY23 $5.5MFY24 $6.2MFY25 $-1.7MFY26 $7.2M

Free Cash Flow

+330.8% YoY

$6.8MFY 2026

FY23 —FY24 —FY25 $-2.9MFY26 $6.8M

Metric	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Revenue	$77.5M +16.5%	$66.6M +23.7%	$53.8M +16.8%	$46.1M +9.6%	$42.0M +10.5%	$38.0M
Net Income	$13.7M +52.2%	$9.0M +322.1%	$2.1M -69.9%	$7.1M +54.7%	$4.6M -25.9%	$6.2M
Operating Income	$13.0M +21.5%	$10.7M +49.0%	$7.2M +24.5%	$5.8M +12.5%	$5.1M +13.2%	$4.5M
EPS (Diluted)	$4.12 +54.3%	$2.67 +345.0%	$0.60 -69.2%	$1.95 +61.2%	$1.21 -22.9%	$1.57
Total Assets	$74.5M +21.8%	$61.2M +16.6%	$52.5M +1.3%	$51.8M +9.5%	$47.3M +17.4%	$40.3M
Total Debt	$17.5M +13.5%	$15.4M +29.1%	$12.0M -6.6%	$12.8M -5.8%	$13.6M -3.4%	$14.1M
Operating Cash Flow	$7.2M +530.6%	$-1.7M -127.0%	$6.2M +14.0%	$5.5M +744.9%	$-847.0K +59.2%	$-2.1M
Free Cash Flow	$6.8M +330.8%	$-2.9M	—	—	$-2.5M +35.4%	$-3.8M

Get alerted when PDEX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for PRO DEX INC including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PDEX

BlackRock, Inc.
$9.0M153,178 sh
VANGUARD CAPITAL MANAGEMENT LLC
$4.8M82,283 sh
DIMENSIONAL FUND ADVISORS LP
$3.3M57,061 sh
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.
$3.1M52,735 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.9M49,636 sh
JPMORGAN CHASE & CO
$1.9M32,287 sh
STATE STREET CORP
$1.8M31,310 sh
GOLDMAN SACHS GROUP INC
$1.1M18,711 sh
Pekin Hardy Strauss, Inc.
$966.1K16,500 sh
BNP PARIBAS FINANCIAL MARKETS
$933.6K15,945 sh

Fund	Value	Shares
BlackRock, Inc.	$9.0M	153,178
VANGUARD CAPITAL MANAGEMENT LLC	$4.8M	82,283
DIMENSIONAL FUND ADVISORS LP	$3.3M	57,061
PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.	$3.1M	52,735
GEODE CAPITAL MANAGEMENT, LLC	$2.9M	49,636
JPMORGAN CHASE & CO	$1.9M	32,287
STATE STREET CORP	$1.8M	31,310
GOLDMAN SACHS GROUP INC	$1.1M	18,711
Pekin Hardy Strauss, Inc.	$966.1K	16,500
BNP PARIBAS FINANCIAL MARKETS	$933.6K	15,945

Companies Similar to PDEX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ELMD

Electromed, Inc.

AI score

Similar quality profile · 3 shared holders

PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.CORSAIR CAPITAL MANAGEMENT, L.P.BAILARD, INC.

PLX

Protalix BioTherapeutics, Inc.

AI score

Similar quality profile · 1 shared holders

BAILARD, INC.

LMAT

LEMAITRE VASCULAR INC

AI score

Similar quality profile · 2 shared holders

MORGAN DEMPSEY CAPITAL MANAGEMENT LLC Lavaca Capital LLC

TCMD

TACTILE SYSTEMS TECHNOLOGY INC

AI score

Similar quality profile · 2 shared holders

PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.BAILARD, INC.

VMD

VIEMED HEALTHCARE, INC.

AI score

Similar quality profile · 3 shared holders

PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.BARD ASSOCIATES INC BAILARD, INC.

TMDX

TransMedics Group, Inc.

AI score

Similar quality profile · 1 shared holders

CORSAIR CAPITAL MANAGEMENT, L.P.

NATR

NATURES SUNSHINE PRODUCTS INC

AI score

Similar quality profile · 1 shared holders

PUNCH & ASSOCIATES INVESTMENT MANAGEMENT, INC.

NAGE

Niagen Bioscience, Inc.

AI score

Similar quality profile

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PDEX on your watchlist

Track score changes the day PRO DEX INC files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PDEX a good stock to buy?

13F Pro's AI-powered analysis of PRO DEX INC (PDEX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PDEX are available on the PDEX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PDEX is classified as a small company.

Which hedge funds own PDEX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PDEX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of PRO DEX INC's investment landscape.